99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 10, 2004, Pages 1399-1404

  Mena, Esther ^a   Camacho, Valle ^a   Estorch, Montserrat ^a   Fuertes, Jordi ^a   Flotats, Albert ^a   Carrió, Ignasi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

99mTc depreotide scintigraphy; Bone involvement; Bone scintigraphy; Lung cancer

Indexed keywords

DEPREOTIDE TC 99M; ETIDRONIC ACID TC 99M; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BRAIN METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GIANT CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; UNDIFFERENTIATED CARCINOMA; BONE TUMOR; CARCINOMA; CLINICAL TRIAL; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 5444264343     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1594-x     Document Type: Article

References (37)

1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S
2. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-58
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
4. Bach PB, Niewoehner DE, Black WC. Screening for lung cancer: the guidelines. Chest 2003;123:83S-8S
5. Tan BB, Flaherty KR, Kazerooni EA, Iannettom MD, American College of Chest Physicians. The solitary pulmonary nodule. Chest 2003;123:89S-96S
6. Valkema R, Steens J, Cleton FJ, Pauwels EK. The diagnostic utility of somatostatin receptor scintigraphy in oncology J Cancer Res Clin Oncol 1996;122:513-32
7. O'Byrne KJ, Carney DN Radiolabeled somatostatine analogue scintigraphy in oncology. Anticancer Drugs 1996;7:33-4
8. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;221:1106-13
9. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Paugerf T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. New trends in peptide receptor radioligands. Q J Nucl Med 2001;45:153-9
10. 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-8
11. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016-22
12. Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M, Jacobstein J. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400-4
13. Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des 2002;8:1827-36
14. Morehead RS, Shih WJ. Tc-99m-labeled somatostatin receptor-binding peptide imaging for a pulmonary nodule Clin Nucl Med 2001;26:910-2
15. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potencial relevance. Yale J Biol Med 1997;70:471-9
16. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours Eur J Nucl Med 1993;20:283-92
17. Leitha T, Meghdadi S, Studnicka M, Wolzt M, Marosi C, Angelberger P, Neumann M, Schlick W, Kletter K, Dudczak R. The role of iodine-123-Tyr-3- octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1993;34:1397-402
18. Breeman WA, De Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser YJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-9
19. 111In-DOTA-lanreotide scintigraphy in patient with tumors of the lung. J Nucl Med 2001;42:1309-15
20. 99mTc depreotide. Semin Nucl Med 2002;32:92-6
21. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S, Munz DL. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224-7
22. Stokkel MP, Kwa BM, Pauwels EK Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Br J Clin Pract 1995;49:235-8
23. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer lines. Life Sci 1994;55:1797-806
24. 99m Tc-P829. Cancer Res 1998; 58:1850-9
25. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer Int J Clin Pract 2003;57:184-6
26. Scutellari PN, Antinolfi G, Galeotti R, Giganti M. Metastatic bone disease. Strategies for imaging. Minerva Med 2003; 94:77-90
27. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG Clin Nucl Med 2003;28:302-7
28. 99mTc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494-501
29. 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735-41
30. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, Le Guludec D. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy J Nucl Med 1999; 40:1602-8
31. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, Serrano J, Venzon DJ, Jensen RT. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040-53
32. Steger W, Amthauer H, Vogl TJ, Wiedenmann B, Steger S, Eichstadt H Detection of bone metastases in patients with neuroendocrine gastrointestinal tumors Radiologe 1999;39:235-40
33. Van de Wiele C, Signore A, Dierckx RA. Peptide receptor imaging. advances in the diagnosis of pulmonary diseases. Am J Respir Med 2002;1:177-83
34. Vanhagen PM, krenninf EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, Laissure I, Hoogstede HC, Lamberts SW. Somatostatin analogue scintigraphy in granulomatous diseases Eur J Nucl Med 1994;21:497-502
35. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:497-502
36. Krenning EP, Kwekkeboom DJ, Bakker W. Somatostatin receptor scintigraphy with In-111-DTPA-D-Phe1 and I-131-Try-3-octreotide the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31
37. Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002;32:276-92